The Most Worrisome Study at AHA 2024
A trial on percutaneous left atrial appendage closure combined with AF ablation vs ablation and DOACs raises concerns about a potential wave of overuse of a new combo procedure.| Medscape
A trial on percutaneous left atrial appendage closure combined with AF ablation vs ablation and DOACs raises concerns about a potential wave of overuse of a new combo procedure.| Medscape
The OPTION trial of Watchman after ablation for AF vs anticoagulation was positive. John Mandrola questions the conclusions and fears the rise in percutaneous left atrial appendage closure procedures.| Medscape
Patients with obesity face unique challenges in healthcare settings. Learn how to create a practice environment that promotes healing.| Medscape
The REFINE-ICD trial identified patients at high arrhythmic risk post myocardial infarction, yet didn’t show a benefit for a prophylactic implantable cardioverter-defibrillator.| Medscape
Will reassuring safety data and a good efficacy signal increase use of digoxin in heart failure? John Mandrola MD reviews the DIGIT- HF trial from the 2025 European Society of Cardiology congress.| Medscape
Seemingly conflicting data from trials on whether to use beta-blockers post myocardial infarction point in the same direction, argues John Mandrola, MD, in reviewing BETAMI/DANBLOCK and REBOOT.| Medscape
Cardiology : Welcome to theheart.org | Medscape Cardiology, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles, and trending stories.| www.medscape.com
In a mystery of cardiology and neurology, the empirical evidence for cerebral protection in transcatheter aortic valve implantation is unclear despite plausibility and data, writes John Mandrola, MD.| Medscape
Today on Medscape : Get the latest medical news, clinical trial coverage, drug updates, journal articles, CME activities & more on Medscape. A free resource for physicians.| www.medscape.com
More and more providers are beginning to incorporate the new Practical Geriatric Assessment into their practices.| Medscape
by Jon McKenna The post [Medscape] Medscape Physicians and Taxes Report 2025 appeared first on Cerebral Tax Advisors.| Cerebral Tax Advisors
A fifth paper authored by former Duke University physician and cancer researcher Anil Potti has been retracted. Is he setting a record?| Medscape
Dr. Anil Potti and colleagues have retracted papers from the New England Journal of Medicine, Lancet Oncology, Nature Medicine, and Journal of Clinical Oncology.| Medscape
Research into using gene signatures to predict responses to chemotherapy, developed at Duke University, has been called into question.| Medscape
Alzheimer's Association International Conference (AAIC) 2024 : Read clinically focused news coverage of key developments from AAIC 2024| Medscape
Why has only one researcher has been punished for the false research in cancer genomics at Duke University that led to clinical trials in hundreds of patients?| Medscape
An expanded indication based on a dubious post hoc analysis of GUIDE-HF should not allow the CardioMEMS HF system to become the therapeutic fashion, writes John Mandrola, MD.| Medscape
